These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30791762)

  • 1. Apoptosis signal-regulating kinase-1 as a therapeutic target in nonalcoholic fatty liver disease.
    Kefala G; Tziomalos K
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):189-191. PubMed ID: 30791762
    [No Abstract]   [Full Text] [Related]  

  • 2. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
    Loomba R; Lawitz E; Mantry PS; Jayakumar S; Caldwell SH; Arnold H; Diehl AM; Djedjos CS; Han L; Myers RP; Subramanian GM; McHutchison JG; Goodman ZD; Afdhal NH; Charlton MR;
    Hepatology; 2018 Feb; 67(2):549-559. PubMed ID: 28892558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver disease: Conscious uncoupling in NASH.
    Villanueva MT
    Nat Rev Drug Discov; 2017 Mar; 16(4):238-239. PubMed ID: 28356593
    [No Abstract]   [Full Text] [Related]  

  • 4. The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.
    Zhang P; Wang PX; Zhao LP; Zhang X; Ji YX; Zhang XJ; Fang C; Lu YX; Yang X; Gao MM; Zhang Y; Tian S; Zhu XY; Gong J; Ma XL; Li F; Wang Z; Huang Z; She ZG; Li H
    Nat Med; 2018 Jan; 24(1):84-94. PubMed ID: 29227477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators.
    Colak Y; Yesil A; Mutlu HH; Caklili OT; Ulasoglu C; Senates E; Takir M; Kostek O; Yilmaz Y; Yilmaz Enc F; Tasan G; Tuncer I
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):311-9. PubMed ID: 25267960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic application of apoptosis signal-regulating kinase 1 inhibitors.
    Fujisawa T
    Adv Biol Regul; 2017 Dec; 66():85-90. PubMed ID: 29066277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
    Wree A; Mehal WZ; Feldstein AE
    Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
    Sun X; Zhang Y; Xie M
    Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis signal-regulating kinase 1 (ASK1) as a therapeutic target for neurological diseases.
    Takenaka S; Fujisawa T; Ichijo H
    Expert Opin Ther Targets; 2020 Nov; 24(11):1061-1064. PubMed ID: 32930624
    [No Abstract]   [Full Text] [Related]  

  • 10. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway.
    Fan Y; He Z; Wang W; Li J; Hu A; Li L; Yan L; Li Z; Yin Q
    Biomed Pharmacother; 2018 Oct; 106():733-737. PubMed ID: 29990865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of histone deacetylase on nonalcoholic fatty liver disease.
    Fu S; Yu M; Tan Y; Liu D
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):353-361. PubMed ID: 33213187
    [No Abstract]   [Full Text] [Related]  

  • 12. Total aralosides of aralia elata (Miq) seem (TASAES) ameliorate nonalcoholic steatohepatitis by modulating IRE1α-mediated JNK and NF-κB pathways in ApoE-/- mice.
    Luo Y; Dong X; Yu Y; Sun G; Sun X
    J Ethnopharmacol; 2015 Apr; 163():241-50. PubMed ID: 25655997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspase Recruitment Domain Protein 6 Protects Against Hepatic Steatosis and Insulin Resistance by Suppressing Apoptosis Signal-Regulating Kinase 1.
    Sun P; Zeng Q; Cheng D; Zhang K; Zheng J; Liu Y; Yuan YF; Tang YD
    Hepatology; 2018 Dec; 68(6):2212-2229. PubMed ID: 29729191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
    Yamamoto E; Dong YF; Kataoka K; Yamashita T; Tokutomi Y; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2008 Sep; 52(3):573-80. PubMed ID: 18678790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FATP2-targeted therapies - A role beyond fatty liver disease.
    Qiu P; Wang H; Zhang M; Zhang M; Peng R; Zhao Q; Liu J
    Pharmacol Res; 2020 Nov; 161():105228. PubMed ID: 33027714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting incretin hormones and the ASK-1 pathway as therapeutic options in the treatment of non-alcoholic steatohepatitis.
    Kovalic AJ; Satapathy SK; Chalasani N
    Hepatol Int; 2018 Mar; 12(2):97-106. PubMed ID: 29600430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.
    Wang PX; Ji YX; Zhang XJ; Zhao LP; Yan ZZ; Zhang P; Shen LJ; Yang X; Fang J; Tian S; Zhu XY; Gong J; Zhang X; Wei QF; Wang Y; Li J; Wan L; Xie Q; She ZG; Wang Z; Huang Z; Li H
    Nat Med; 2017 Apr; 23(4):439-449. PubMed ID: 28218919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation and function of apoptosis signal-regulating kinase 1 in rheumatoid arthritis.
    Nygaard G; Di Paolo JA; Hammaker D; Boyle DL; Budas G; Notte GT; Mikaelian I; Barry V; Firestein GS
    Biochem Pharmacol; 2018 May; 151():282-290. PubMed ID: 29408488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
    Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
    Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.